Compare Ascendis Pharma A/S (ASND) vs Workiva Inc (WK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs Workiva Inc — how do they compare? Ascendis Pharma A/S trades at $257 (market cap $16.67B), while Workiva Inc trades at $68.14 (market cap $3.76B). The key difference: Ascendis Pharma A/S is far larger — about 4.4× Workiva Inc's market cap, and Ascendis Pharma A/S is trading nearer its 52-week high, Workiva Inc nearer its low. Which is the better fit depends on your goals.
| ASND | WK | |
|---|---|---|
Market Cap | $16.67B | $3.76B |
Sector | Health | Technology |
52-Week High | $277.18 | $93.31 |
52-Week Low | $189.74 | $44.31 |
Enterprise Value | $17.04B | $3.73B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $255.46, showing minimal daily movement (-0.06%). The stock maintains a bullish technical outlook with strong analyst support (92% buy ratings) and a consensus price target of $309.75, representing 21% upside potential. Recent developments include positive clinical trial updates for TransCon CNP in achondroplasia and inclusion in multiple Russell indexes, signaling growing institutional recognition. Revenue growth has been robust, increasing from $51M in 2022 to $720M in 2025, though the company remains unprofitable with a net loss of $228M in 2025.
ASND presents a growth investment opportunity with multiple product catalysts and improving financial trajectory, though significant risks remain. The company's premium valuation (P/E 29.05, P/S 15.68) reflects high growth expectations, while negative shareholder equity and substantial debt require careful monitoring. Positive cash flow generation since 2024 and upcoming regulatory milestones provide potential upside, but execution risks and clinical trial outcomes could impact shareholder value.
Workiva (WK) trades at $68.07, up 1.11% today, with strong technical momentum and bullish moving averages. The company has delivered three consecutive quarterly earnings beats, with Q2 2026 revenue of $255 million exceeding guidance. Analyst sentiment remains overwhelmingly positive with 16 buy ratings and a $69 consensus target. The stock shows robust revenue growth but elevated valuation multiples with a P/E of 82.2.
Outlook remains constructive given consistent earnings outperformance and strong subscription growth, though high valuation and negative net income in 2025 present risks. The company's AI platform expansion and Fortune 500 customer base support long-term growth potential, but investors should monitor profitability improvement and competitive pressures in the compliance software space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Workiva Inc
Workiva is a leading provider of cloud-based platforms for complex reporting and compliance. It enables organizations to connect and manage data across financial reporting, ESG (Environmental, Social, and Governance), and GRC (Governance, Risk, and Compliance), serving as a single source of truth for auditable, transparent disclosures to regulators and stakeholders.
Read more on WK →
